Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Very High-Risk T-Lineage Acute Lymphoblastic Leukemia
NCT06253637Phase 2Active, not recruiting
- Sponsor
- GIMEMA
- Start
- Oct 2024
- Primary completion
- Oct 2029
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in acute lymphoblastic leukemia (ALL), sponsored by GIMEMA. Started Oct 2024; status: active, not recruiting.
02
Drugs
daratumumab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06253637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253637.